


Comparison: other vs 'Placebo'



Comparison: other vs 'Placebo' (Random Effects Model) 95%-CI **Treatment** OR Afatinib 1.64 [0.65; 4.12] Afatinib+EGF inhibitor 3.49 [0.48; 25.45] 23.73 [1.02; 550.41] Almonertinib 3.55 [0.84; 15.08] Amivantamab + Lazertinib 1.58 [0.66; 3.75] Chemotherapy 1.00 [0.40; 2.49] Dacomitinib 2.30 [0.15; 34.97] **DHFR** inhibitor 1.09 [0.54; 2.20] **Erlotinib** 0.35 [0.01; 11.35] Erlotinib+Autophagy inhibitor 0.86 [0.21; 3.45] Erlotinib+chemotherapy 5.52 [0.20; 149.42] Erlotinib+ER inhibitor Erlotinib+HER3 inhibitor(18 mg/kg) 0.73 [0.08; 6.64] Erlotinib+HGF inhibitor 3.47 [0.10; 120.62] 2.90 [0.47; 18.04] Erlotinib+IGF inhibitor Erlotinib+IGF inhibitor(16mg/kg) 5.45 [0.20; 148.83] Erlotinib+MET inhibitor 1.09 [0.40; 2.99] Erlotinib+MMP inhibitor 0.12 [0.00; 2.84] [1.62; 8.40] Erlotinib+VEGF inhibitor 3.69 Gefitinib 1.07 [0.46; 2.50] Gefitinib/Erlotinib 0.70 [0.12; 4.00] Gefitinib+chemotherapy 1.49 [0.43; 5.17] 32.56 [6.62; 160.08] Gefitinib+VEGF inhibitor [0.42; 5.25] Lazertinib 1.49 [0.40; 3.36] Osimertinib 1.15 Osimertinib+chemotherapy 3.07 [0.52; 18.24] Osimertinib+VEGF inhibitor 2.16 [0.42; 10.98] Placebo 1.00 0.59 [0.02; 18.91] Rociletinib(625 mg) **VEGF** inhibitor 6.04 [2.01; 18.12]

0.1

10

100

0.01

Comparison: other vs 'Placebo'

